Table 1.
Phase I studies on intraperitoneal chemotherapy using taxanes for the treatment of gastric cancer with peritoneal carcinomatosis
| Ref. | n | Intraperitoneally administered taxanes | Initial dose (mg/m2) | MTD (mg/m2) | RD (mg/m2) | DLT |
| Kodera et al[42] | 4 | PTX | 60 | - | - | - |
| Fushida et al[26] | 24 | DOC | 25 | 60 | 45 | Abdominal pain and |
| diarrhea | ||||||
| Ishigami et al[45] | 9 | PTX | 20 | 30 | 20 | Febrile neutropenia and diarrhea |
| Fujiwara et al[43] | 12 | DOC | 40 | - | 60 | - |
| Kurita et al[44] | 18 | PTX | 40 | 90 | 80 | Leukocytopenia |
| Fushida et al[16] | 12 | DOC | 35 | 50 | 45 | Febrile neutropenia and diarrhea |
MTD: Maximum tolerated dose; RD: Recommended dose; DLT: Dose-limiting toxicities; PTX: Paclitaxel; DOC: Docetaxel.